PTC Therapeutics reported second-quarter 2026 results with revenue of $360.5M and net income attributable to common stockholders of $83.5M, driven by strong launch momentum for Sephience and a shift in the company’s product mix toward U.S. sales; diluted EPS was $0.92, versus a loss in the year‑ago quarter.
Financial Highlights
- Revenue: $360.5M for Q2 2026, up from $178.9M in the year-ago quarter; YoY change 101.5%.
- Net income: $83.5M attributable to common stockholders for Q2 2026, versus $(64.8)M in the year-ago quarter (turned positive YoY).
- Diluted EPS: $0.92 for Q2 2026, compared with $(0.83) in the year-ago quarter.
Business Highlights
- Sephience launch drove material growth, adding roughly $151M in net product sales in Q2 and lifting total product revenue versus the prior year.
- U.S. became the primary sales driver with strong demand for Sephience and Emflaza; Translarna international sales declined after a negative EU opinion.
- Regulatory and partnership milestones included Sephience approvals in the U.S., EU, Japan and Brazil, and a $50M milestone triggered by Novartis’ votoplam Phase 3 initiation.
- Company reallocated R&D spending to priority splicing and inflammation/ferroptosis programs while advancing clinical programs including votoplam, PTC612 and PTC844.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.